Literature DB >> 15482536

Liver cell transplantation leads to repopulation and functional correction in a mouse model of Wilson's disease.

Katrina J Allen1, Daphne My Cheah, Paul Fa Wright, Sophie Gazeas, Nicole E Pettigrew-Buck, Yolanda H Deal, Julian Fb Mercer, Robert Williamson.   

Abstract

BACKGROUND AND AIM: The toxic milk (tx) mouse is a non-fatal animal model for the metabolic liver disorder, Wilson's disease. The tx mouse has a mutated gene for a copper-transporting protein, causing early copper accumulation in the liver and late accumulation in other tissues. The present study investigated the efficacy of liver cell transplantation (LCT) to correct the tx mouse phenotype.
METHODS: Congenic hepatocytes were isolated and intrasplenically transplanted into 3-4-month-old tx mice, which were then placed on various copper-loaded diets to examine its influence on repopulation by transplanted cells. The control animals were age-matched untransplanted tx mice. Liver repopulation was determined by comparisons of restriction fragment length polymorphism ratios (DNA and mRNA), and copper levels were measured by atomic absorption spectroscopy.
RESULTS: Repopulation in recipient tx mice was detected in 11 of 25 animals (44%) at 4 months after LCT. Dietary copper loading (whether given before or after LCT, or both) provided no growth advantage for donor cells, with similar repopulation incidences in all copper treatment groups. Overall, liver copper levels were significantly lower in repopulated animals (538 +/- 68 microg/g, n = 11) compared to non-repopulated animals (866 +/- 62 microg/g, n = 14) and untreated controls (910 +/- 103 microg/g, n = 6; P < 0.05). This effect was also seen in the kidney and spleen. Brain copper levels remained unchanged.
CONCLUSION: Transplanted liver cells can proliferate and correct a non-fatal metabolic liver disease, with some restoration of hepatic copper homeostasis after 4 months leading to reduced copper levels in the liver and extrahepatic tissues, but not in the brain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15482536     DOI: 10.1111/j.1440-1746.2004.03451.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  14 in total

Review 1.  Embryonic and induced pluripotent stem cells as a model for liver disease.

Authors:  Hiroshi Yagi; Edgar Tafaleng; Masaki Nagaya; Marc C Hansel; Stephen C Strom; Ira J Fox; Alejandro Soto-Gutierrez
Journal:  Crit Rev Biomed Eng       Date:  2009

2.  New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Authors:  Jennifer R Ferrer; Attasit Chokechanachaisakul; Jason A Wertheim
Journal:  Curr Transplant Rep       Date:  2015-06-01

3.  Correction of copper metabolism is not sustained long term in Wilson's disease mice post bone marrow transplantation.

Authors:  Nicole E Buck; Daphne M Y Cheah; Ngaire J Elwood; Paul F A Wright; Katrina J Allen
Journal:  Hepatol Int       Date:  2007-12-28       Impact factor: 6.047

4.  In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice.

Authors:  Nicole K Paulk; Karsten Wursthorn; Annelise Haft; Carl Pelz; Gregory Clarke; Amy H Newell; Susan B Olson; Cary O Harding; Milton J Finegold; Raymond L Bateman; John F Witte; Ronald McClard; Markus Grompe
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

5.  AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo.

Authors:  Nicole K Paulk; Laura Marquez Loza; Milton J Finegold; Markus Grompe
Journal:  Hum Gene Ther       Date:  2012-06-25       Impact factor: 5.695

6.  Hepatocyte transplantation (HTx) corrects selected neurometabolic abnormalities in murine intermediate maple syrup urine disease (iMSUD).

Authors:  Kristen J Skvorak; Elizabeth J Hager; Erland Arning; Teodoro Bottiglieri; Harbhajan S Paul; Stephen C Strom; Gregg E Homanics; Qin Sun; Erwin E W Jansen; Cornelis Jakobs; William J Zinnanti; K Michael Gibson
Journal:  Biochim Biophys Acta       Date:  2009-08-19

7.  Magnetic targeting of iron-oxide-labeled fluorescent hepatoma cells to the liver.

Authors:  Alain Luciani; Claire Wilhelm; Patrick Bruneval; Patrick Cunin; Gwennhael Autret; Alain Rahmouni; Olivier Clément; Florence Gazeau
Journal:  Eur Radiol       Date:  2009-01-10       Impact factor: 5.315

Review 8.  Cell therapy to remove excess copper in Wilson's disease.

Authors:  Sanjeev Gupta
Journal:  Ann N Y Acad Sci       Date:  2014-05       Impact factor: 5.691

9.  Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo.

Authors:  Nicole K Paulk; Karsten Wursthorn; Zhongya Wang; Milton J Finegold; Mark A Kay; Markus Grompe
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

10.  Longitudinal analysis of serum miR-122 in a rat model of Wilson's disease.

Authors:  Ramsi Siaj; Vanessa Sauer; Sandra Stöppeler; Joachim Gerß; Hans-Ullrich Spiegel; Gabriele Köhler; Andree Zibert; Hartmut H-J Schmidt
Journal:  Hepatol Int       Date:  2012-02-11       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.